Edition:
United States

Zhejiang Hisun Pharmaceutical Co Ltd (600267.SS)

600267.SS on Shanghai Stock Exchange

12.45CNY
2:59am EDT
Change (% chg)

¥0.35 (+2.89%)
Prev Close
¥12.10
Open
¥12.10
Day's High
¥12.51
Day's Low
¥12.05
Volume
7,369,552
Avg. Vol
4,539,431
52-wk High
¥15.08
52-wk Low
¥10.24

Latest Key Developments (Source: Significant Developments)

Zhejiang Hisun Pharmaceutical sub-subsidiary passes FDA approval
Monday, 11 Sep 2017 10:30am EDT 

Sept 11(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::* Says its Zhejiang-based sub-subsidiary received FDA approval for metformin sustained release tablet from U.S Food and Drug Administration .* Company will be able to sell its metformin sustained release tablet in the United States after receiving the FDA approval.  Full Article

Zhejiang Hisun Pharmaceutical to set up pharmaceutical unit in Zhejiang
Thursday, 10 Aug 2017 11:17pm EDT 

Aug 11(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:Says it plans to set up a wholly owned pharmaceutical unit in Zhejiang, with registered capital of 10 million yuan .  Full Article

Zhejiang Hisun Pharmaceutical to pay FY 2016 annual div on July 7
Friday, 30 Jun 2017 03:09am EDT 

June 30(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::* Says it will pay FY 2016 dividend to shareholders of record on July 6.* The company's shares will be traded ex-right and ex-dividend on July 7 and the dividend will be paid on July 7.  Full Article

Zhejiang Hisun Pharmaceutical receives GMP certificate
Wednesday, 28 Jun 2017 02:24am EDT 

June 28(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::* Says it received goods manufacture practice (GMP) certificate from Zhejiang Food and Drug Administration.* Says certificate issued to mycophenolate mofetil manufactured by the company and the valid period is until June 25, 2022.  Full Article

Zhejiang Hisun Pharmaceutical receives administrative order
Tuesday, 25 Apr 2017 05:10am EDT 

April 25(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::* Says it received an administrative order from Zhejiang Regulatory Bureau of China Securities Regulatory Commission, regarding information disclosure and false financial report .  Full Article

Zhejiang Hisun Pharmaceutical amends FY 2016 net profit outlook
Wednesday, 29 Mar 2017 06:00am EDT 

Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> : Says net loss for FY 2016 is 94 million yuan . Says in the previous outlook, the company expected the net profit for FY 2016 to increase by 260 percent to 300 percent . Says the net profit of FY 2015 was 13.6 million yuan .Comments that increased advance receipts instead of revenue is the main reason for the forecast.  Full Article

Zhejiang Hisun Pharmaceutical gets approval for three drugs to enter clinical trials
Thursday, 16 Mar 2017 06:03am EDT 

Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> : Says it got approval from China Food and Drug Administration to do clinical trials for three kinds of crud drugs .The three drugs are used for pulmonary tuberculosis, mammary cancer and hematological malignancies treatment respectively.  Full Article

Zhejiang Hisun Pharmaceutical receives GMP certificate
Wednesday, 15 Mar 2017 03:36am EDT 

Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> : Says it received goods manufacture practice(GMP) certificate from Zhejiang Food and Drug Administration .Says the certificate issued to lyophilized powder for injection manufactured by the co and the valid period is until March 5, 2022.  Full Article

Celsion Co, Zhejiang Hisun Pharma sign deal for development of GEN-1 immuno-oncology therapy
Tuesday, 9 Aug 2016 09:00am EDT 

Celsion Corp : Co, Zhejiang Hisun Pharma sign technology transfer, manufacturing and commercial supply deal for development of GEN-1 immuno-oncology therapy . Hisun will collaborate with Celsion around regulatory approval activities for GEN-1 with CFDA . Agreement has targeted unit costs for clinical supplies of GEN-1 that are substantially competitive with company's current suppliers .Will provide Hisun a percentage certain of China's commercial unit demand, and separately of global commercial unit demand.  Full Article

Zhejiang Hisun Pharmaceutical unit gets GMP certificate
Sunday, 24 Jul 2016 10:53pm EDT 

Zhejiang Hisun Pharmaceutical Co., Ltd. <600267.SS>: Says its unit receives goods manufacture practice (GMP) certificate .Says certificate issued to the unit's imported drug packing production line and the valid period is until July 3, 2021.  Full Article

BRIEF-Zhejiang Hisun Pharmaceutical sub-subsidiary passes FDA approval

* Says its Zhejiang-based sub-subsidiary received FDA approval for metformin sustained release tablet from U.S Food and Drug Administration